BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Patel JM, Vartabedian VF, Kim MC, He S, Kang SM, Selvaraj P. Influenza virus-like particles engineered by protein transfer with tumor-associated antigens induces protective antitumor immunity. Biotechnol Bioeng 2015;112:1102-10. [PMID: 25689082 DOI: 10.1002/bit.25537] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Liu SS, Liu YS, Guo XY, Murakami Y, Yang G, Gao XD, Kinoshita T, Fujita M. A knockout cell library of GPI biosynthetic genes for functional studies of GPI-anchored proteins. Commun Biol 2021;4:777. [PMID: 34162996 DOI: 10.1038/s42003-021-02337-1] [Reference Citation Analysis]
2 Metzner C, Salmons B, Günzburg WH, Dangerfield JA. Comment on Patel et al; "Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses" Nanomedicine, 2015. 11(5): p. 1097-107. Nanomedicine 2016;12:665-6. [PMID: 26593637 DOI: 10.1016/j.nano.2015.10.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
3 Ong HK, Tan WS, Ho KL. Virus like particles as a platform for cancer vaccine development. PeerJ 2017;5:e4053. [PMID: 29158984 DOI: 10.7717/peerj.4053] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
4 Sander AF, Lollini PL. Virus-like antigen display for cancer vaccine development, what is the potential? Expert Rev Vaccines 2018;17:285-8. [PMID: 29560746 DOI: 10.1080/14760584.2018.1455505] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
5 Navarro-Ocón A, Blaya-Cánovas JL, López-Tejada A, Blancas I, Sánchez-Martín RM, Garrido MJ, Griñán-Lisón C, Calahorra J, Cara FE, Ruiz-Cabello F, Marchal JA, Aptsiauri N, Granados-Principal S. Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer. Pharmaceutics 2022;14:505. [PMID: 35335881 DOI: 10.3390/pharmaceutics14030505] [Reference Citation Analysis]
6 McFall-Boegeman H, Huang X. Mechanisms of cellular and humoral immunity through the lens of VLP-based vaccines. Expert Rev Vaccines 2022. [PMID: 35023430 DOI: 10.1080/14760584.2022.2029415] [Reference Citation Analysis]
7 Brune KD, Leneghan DB, Brian IJ, Ishizuka AS, Bachmann MF, Draper SJ, Biswas S, Howarth M. Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization. Sci Rep 2016;6:19234. [PMID: 26781591 DOI: 10.1038/srep19234] [Cited by in Crossref: 172] [Cited by in F6Publishing: 152] [Article Influence: 28.7] [Reference Citation Analysis]
8 Vijayan V, Mohapatra A, Uthaman S, Park IK. Recent Advances in Nanovaccines Using Biomimetic Immunomodulatory Materials. Pharmaceutics 2019;11:E534. [PMID: 31615112 DOI: 10.3390/pharmaceutics11100534] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 10.3] [Reference Citation Analysis]
9 Li Z, Zhong L, He J, Huang Y, Zhao Y. Development and application of reverse genetic technology for the influenza virus. Virus Genes 2021;57:151-63. [PMID: 33528730 DOI: 10.1007/s11262-020-01822-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Liyanage PY, Hettiarachchi SD, Zhou Y, Ouhtit A, Seven ES, Oztan CY, Celik E, Leblanc RM. Nanoparticle-mediated targeted drug delivery for breast cancer treatment. Biochim Biophys Acta Rev Cancer 2019;1871:419-33. [PMID: 31034927 DOI: 10.1016/j.bbcan.2019.04.006] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 13.7] [Reference Citation Analysis]
11 Heider S, Reimhult E, Metzner C. Real-time analysis of protein and protein mixture interaction with lipid bilayers. Biochimica et Biophysica Acta (BBA) - Biomembranes 2018;1860:319-28. [DOI: 10.1016/j.bbamem.2017.10.024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
12 Hu H, Steinmetz NF. Development of a Virus-Like Particle-Based Anti-HER2 Breast Cancer Vaccine. Cancers (Basel) 2021;13:2909. [PMID: 34200802 DOI: 10.3390/cancers13122909] [Reference Citation Analysis]
13 Heider S, Kleinberger S, Kochan F, Dangerfield JA, Metzner C. Immune Protection of Retroviral Vectors Upon Molecular Painting with the Complement Regulatory Protein CD59. Mol Biotechnol 2016;58:480-8. [PMID: 27170144 DOI: 10.1007/s12033-016-9944-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Dewangan HK, Tomar S. Nanovaccine for transdermal delivery system. Journal of Drug Delivery Science and Technology 2022;67:102988. [DOI: 10.1016/j.jddst.2021.102988] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Zepeda-Cervantes J, Ramírez-Jarquín JO, Vaca L. Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs. Front Immunol 2020;11:1100. [PMID: 32582186 DOI: 10.3389/fimmu.2020.01100] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 12.5] [Reference Citation Analysis]
16 Bernocchi B, Carpentier R, Lantier I, Ducournau C, Dimier-Poisson I, Betbeder D. Mechanisms allowing protein delivery in nasal mucosa using NPL nanoparticles. J Control Release 2016;232:42-50. [PMID: 27080572 DOI: 10.1016/j.jconrel.2016.04.014] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
17 Allahverdiyev A, Tari G, Bagirova M, Abamor ES. Current Approaches in Development of Immunotherapeutic Vaccines for Breast Cancer. J Breast Cancer 2018;21:343-53. [PMID: 30607155 DOI: 10.4048/jbc.2018.21.e47] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
18 Brune KD, Howarth M. New Routes and Opportunities for Modular Construction of Particulate Vaccines: Stick, Click, and Glue. Front Immunol 2018;9:1432. [PMID: 29997617 DOI: 10.3389/fimmu.2018.01432] [Cited by in Crossref: 57] [Cited by in F6Publishing: 44] [Article Influence: 14.3] [Reference Citation Analysis]
19 Matabaro E, He Z, Liu YS, Zhang HJ, Gao XD, Fujita M. Molecular switching system using glycosylphosphatidylinositol to select cells highly expressing recombinant proteins. Sci Rep 2017;7:4033. [PMID: 28642584 DOI: 10.1038/s41598-017-04330-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
20 Bommireddy R, Stone S, Bhatnagar N, Kumari P, Munoz LE, Oh J, Kim KH, Berry JTL, Jacobsen KM, Jaafar L, Naing SH, Blackerby AN, Gaag TV, Wright CN, Lai L, Pack CD, Ramachandiran S, Suthar MS, Kang SM, Kumar M, Reddy SJC, Selvaraj P. Influenza Virus-like Particle-Based Hybrid Vaccine Containing RBD Induces Immunity against Influenza and SARS-CoV-2 Viruses. Vaccines (Basel) 2022;10:944. [PMID: 35746552 DOI: 10.3390/vaccines10060944] [Reference Citation Analysis]
21 Patel JM, Vartabedian VF, Bozeman EN, Caoyonan BE, Srivatsan S, Pack CD, Dey P, D'Souza MJ, Yang L, Selvaraj P. Plasma membrane vesicles decorated with glycolipid-anchored antigens and adjuvants via protein transfer as an antigen delivery platform for inhibition of tumor growth. Biomaterials 2016;74:231-44. [PMID: 26461116 DOI: 10.1016/j.biomaterials.2015.09.031] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
22 Heider S, Dangerfield JA, Metzner C. Biomedical applications of glycosylphosphatidylinositol-anchored proteins. J Lipid Res 2016;57:1778-88. [PMID: 27542385 DOI: 10.1194/jlr.R070201] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
23 Bernasconi V, Bernocchi B, Ye L, Lê MQ, Omokanye A, Carpentier R, Schön K, Saelens X, Staeheli P, Betbeder D, Lycke N. Porous Nanoparticles With Self-Adjuvanting M2e-Fusion Protein and Recombinant Hemagglutinin Provide Strong and Broadly Protective Immunity Against Influenza Virus Infections. Front Immunol 2018;9:2060. [PMID: 30271406 DOI: 10.3389/fimmu.2018.02060] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]